Erin D. Michos, MD, MHS

AHA Guidelines and Patient Mortality

Video content above is prompted by the following:

Please discuss atherosclerotic cardiovascular disease (ASCVD).

Videos

Atherosclerotic cardiovascular disease (ASCVD) is a condition characterized by the buildup of atherosclerotic plaques within arterial walls, leading to narrowed and hardened arteries. This process can result in reduced blood flow and increased risk of cardiovascular events such as heart attacks and strokes. Risk factors include high cholesterol, hypertension, smoking, diabetes, and a sedentary lifestyle. Management involves lifestyle modifications, pharmacotherapy, and sometimes surgical interventions. Early detection and intervention are crucial in preventing the progression of ASCVD and reducing associated morbidity and mortality.

Panelists discuss how effective management of dyslipidemia through adherence to AHA guidelines is crucial for reducing cardiovascular mortality rates and improving patient outcomes.

AHA Guidelines and Patient Mortality 

Prevalence of Cardiovascular Disease

Can you review the current prevalence and effects of cardiovascular disease in the United States?

In your opinion, what is contributing to the “rising tide” of this disease?

Please discuss the importance of dyslipidemia management in preventing and managing atherosclerotic cardiovascular disease (ASCVD).

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality in the United States, with a significant prevalence affecting millions. Contributing factors to the increasing incidence include lifestyle changes, obesity, diabetes, and hypertension. Dyslipidemia management is crucial in preventing and managing atherosclerotic cardiovascular disease (ASCVD) as it directly influences lipid levels, reducing the risk of plaque formation and subsequent cardiovascular events. Effective management strategies, including lifestyle modifications and pharmacotherapy, are essential in mitigating the impact of CVD and improving patient outcomes.

Panelists discuss how cardiovascular disease remains a leading health concern in the United States, examining its rising prevalence, risk factors such as dyslipidemia, and management strategies aligned with AHA guidelines to reduce patient mortality.

The panelists stress the significance of a comprehensive approach to patient care.

Cardiometabolic Medicine: Seeing the Patient as a Whole

The panelists stress the significance of a comprehensive approach to patient care, acknowledging the interconnected nature of cardiovascular, kidney, endocrine, and obesity-related benefits, and highlighting that addressing secondary diseases can minimize overall disease risk in patients.

Michael Koren, MD addresses the challenges posed by prior authorization.

Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

Video content above is prompted by the following questions:

How does your office handle payer approval/prior authorization for lipid lower medication? Are there any tips to help with getting approval?

How is help with co pay assistance programs coordinated in your practice to help increase accessibility and affordability?

Michael Koren, MD addresses the challenges posed by prior authorization and the diminished role of pharmaceutical sales representatives in informing providers about medication advancements, leading to a disconnect in the provider's treatment arsenal.

Erin D. Michos, MD, MHS

Articles